• MediciNova To Receive Japanese Patent Covering MN-001 To Treat NAFLD And NASH

    • October 30, 2019
    • Posted By : admin
    • 0 Comment
    •   11 views

    Biopharmaceutical company, MediciNova, Inc has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-001 (tipelukast) for the treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

    Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than December 2032. The allowed claims cover MN-001 for treating a patient with NAFLD or NASH. The allowed claims also cover MN-001 for reducing liver inflammation in a patient with NAFLD or NASH. The allowed claims cover oral administration, including tablets and capsules, as well as liquid dosage forms.

    Yuichi Iwaki, MD, PhD, president and CEO of MediciNova, Inc. commented, “We are very pleased to receive notice that this new patent will be granted as we believe it could substantially increase the potential value of MN-001. We previously reported positive results from a phase 2 clinical trial of MN-001 that enrolled NAFLD and NASH patients with hypertriglyceridemia. The US FDA has granted Fast Track designation for MN-001 for the treatment of NASH with fibrosis.”

    MN-001 (tipelukast) is a novel, orally bioavailable small molecule compound thought to exert its effects through several mechanisms to produce its anti-inflammatory and anti-fibrotic activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterases (PDE) (mainly 3 and 4), and inhibition of 5-lipoxygenase (5-LO). The 5-LO/LT pathway has been postulated as a pathogenic factor in fibrosis development, and MN-001’s inhibitory effect on 5-LO and the 5-LO/LT pathway is considered to be a novel approach to treat fibrosis. MN-001 has been shown to down-regulate expression of genes that promote fibrosis including LOXL2, Collagen Type 1 and TIMP-1. MN-001 has also been shown to down-regulate expression of genes that promote inflammation including CCR2 and MCP-1. In addition, histopathological data shows that MN-001 reduces fibrosis in multiple animal models.

  11 views

You Might Also Like

No comments found

LEAVE COMMENT

Archive

Offers
error: Content is protected !!